太龙药业：多元化业务未来可期

中山证券有限责...2025-07-15

研究要点：公司引入国资新股东后，实施了多次回购与员工持股计划，加强了战略性投入。药品制造业务是公司营收的核心，营收占比持续接近八成，对公司整体收入影响显著，主要产品为中药饮片和中药口服液。公司2019 年至2024 年间表现总体稳健，五年复合年增长率（CAGR）达到8.2%。公司口服液产品覆盖面广，双黄连产品突出。产品系列覆盖呼吸系统、心脑血管、消化系统、神经系统、生殖系统等多个治疗领域和中老年、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551315293?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-15 16:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551315293","market":"sh","top_or_hot":-1,"title":"太龙药业：多元化业务未来可期","media":"中山证券有限责...","content":"<div>\n<p>研究要点：公司引入国资新股东后，实施了多次回购与员工持股计划，加强了战略性投入。药品制造业务是公司营收的核心，营收占比持续接近八成，对公司整体收入影响显著，主要产品为中药饮片和中药口服液。公司2019 年至2024 年间表现总体稳健，五年复合年增长率（CAGR）达到8.2%。公司口服液产品覆盖面广，双黄连产品突出。产品系列覆盖呼吸系统、心脑血管、消化系统、神经系统、生殖系统等多个治疗领域和中老年、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715161751954331a0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>太龙药业：多元化业务未来可期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n太龙药业：多元化业务未来可期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-15 16:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715161751954331a0&s=b><strong>中山证券有限责...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>研究要点：公司引入国资新股东后，实施了多次回购与员工持股计划，加强了战略性投入。药品制造业务是公司营收的核心，营收占比持续接近八成，对公司整体收入影响显著，主要产品为中药饮片和中药口服液。公司2019 年至2024 年间表现总体稳健，五年复合年增长率（CAGR）达到8.2%。公司口服液产品覆盖面广，双黄连产品突出。产品系列覆盖呼吸系统、心脑血管、消化系统、神经系统、生殖系统等多个治疗领域和中老年、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715161751954331a0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715161751954331a0&s=b","article_id":"2551315293","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715161751954331a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551315293","pubTimestamp":1752567452,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"药品制造业务是公司营收的核心，营收占比持续接近八成，对公司整体收入影响显著，主要产品为中药饮片和中药口服液。2024 年药品制剂业务受行业相关政策对产品销售的影响，营业收入和营业成本同比下降，毛利率基本持平。公司中药饮片相关业务主要依托两个子公司发展：桐君堂药业有限公司、河南桐君堂道地药材有限公司。2025 年1 季度，中药饮片业务营收约占总营收56.09%，毛利率也有所改善。公司药品研发服务业务由子公司新领先负责开展。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600222":"太龙药业","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"Tailong Pharmaceutical: Diversified business has a promising future","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600222":1},"content_text":"研究要点：公司引入国资新股东后，实施了多次回购与员工持股计划，加强了战略性投入。药品制造业务是公司营收的核心，营收占比持续接近八成，对公司整体收入影响显著，主要产品为中药饮片和中药口服液。公司2019 年至2024 年间表现总体稳健，五年复合年增长率（CAGR）达到8.2%。公司口服液产品覆盖面广，双黄连产品突出。产品系列覆盖呼吸系统、心脑血管、消化系统、神经系统、生殖系统等多个治疗领域和中老年、妇科、儿科等应用领域，主要产品包括双黄连口服液系列、双金连合剂、丹参口服液、生脉饮、藿香正气合剂、五子衍宗口服液等。2024 年药品制剂业务受行业相关政策对产品销售的影响，营业收入和营业成本同比下降，毛利率基本持平。公司中药饮片相关业务主要依托两个子公司发展：桐君堂药业有限公司、河南桐君堂道地药材有限公司。相关业务主要产品为中药饮片，也向上游中药材种植、下游中药煎药服务等渗透。2025 年1 季度，中药饮片业务营收约占总营收56.09%，毛利率也有所改善。公司药品研发服务业务由子公司新领先负责开展。新领先位列“中国医药研发公司五十强企业”，专注为客户提供综合性医药技术研发服务。根据2024 年年报显示，公司合同签订量同比增长11%，受托和自主立项的研发项目中，新增58 项注册申报、32 项药品生产批件、17 项药品通过一致性评价、5项原料药通过审评获批。风险提示：行业竞争格局加剧风险；原材料成本波动风险；集采降价超预期风险；新业务拓展不及预期风险；研发不及预期风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551315293","isCrawlerRequest":true}